ArticleAlimentary pharmacology & therapeutics2022
Circulating bile acid concentrations and non-alcoholic fatty liver disease in Guatemala.
Article in Alimentary pharmacology & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Fatty liver index (FLI): more than a marker of hepatic steatosis.Journal of physiology and biochemistry · 2024Pooled it
- Alterations in Circulating Bile Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.Biomolecules · 2023Pooled it
- Phytochemicals in MASLD: A Focused Review of Gut Microbiome-Linked Mechanisms.Phytotherapy research : PTR · 2026Review
- Chronic intermittent hypoxia exacerbates hepatic steatosis in a microbiota-dependent manner in lean mice.mSystems · 2026Article
- Exploring Active Ingredients and Mechanisms ofMolecules (Basel, Switzerland) · 2026Article
- Chronic liver diseases aggravate radiation-induced intestinal injury through taurocholic acid dysregulation.Journal of translational medicine · 2026Article
- The role of bile acid dynamics in inflammatory bowel disease and metabolic dysfunction-associated steatotic liver disease.Liver research (Beijing, China) · 2026Review
- Towards the clinical use of peripheral bile acids: Recommendations to limit their preanalytical and analytical sources of variability.Practical laboratory medicine · 2025Article
- Pre-diagnostic circulating bile acid concentrations and liver cancer risk: a nested case-control analysis of 12 cohorts.JNCI cancer spectrum · 2025Article
- Gut microbiota and its derived metabolites as silent sculptors of non-alcoholic fatty liver disease development and potential guide for non-invasive clinical diagnostics.Molecular biology reports · 2025Review
- [Analysis and comparison of bile acid metabolism characteristics in children and adults with metabolic- associated fatty liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Review
- Digestive parameters and gut microbiota load and composition along the in vivo piglet gastrointestinal tract.Journal of animal science · 2025Article
- Dietary Influences on Gut Microbiota and Their Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Nutrients · 2024Review
- Bile Acids as Emerging Players at the Intersection of Steatotic Liver Disease and Cardiovascular Diseases.Biomolecules · 2024Review
- Analysis of Serum Bile Acid Profile Characteristics and Identification of New Biomarkers in Lean Metabolic Dysfunction-Associated Fatty Liver Disease Based on LC-MS/MS.Clinical medicine insights. Endocrinology and diabetes · 2024Article
- Effects of cholesterol-lowering probiotics on non-alcoholic fatty liver disease in FXR gene knockout mice.Frontiers in nutrition · 2023Article
- Kaempferol attenuates nonalcoholic steatohepatitis by regulating serum and liver bile acid metabolism.Frontiers in pharmacology · 2022Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
13 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundNon-alcoholic fatty liver disease (NAFLD) is a major liver disease worldwide. Bile acid dysregulation may be a key feature in its pathogenesis and progression.
aimsTo characterise the relationship between bile acid levels and NAFLD at the population level
methodsWe conducted a cross-sectional study in Guatemala in 2016 to examine the prevalence of NAFLD. Participants (n = 415) completed questionnaires, donated blood samples and had a brief medical exam. NAFLD was determined by calculation of the fatty liver index. The levels of 15 circulating bile acids were determined by LC-MS/MS. Adjusted prevalence odds ratios (POR
resultsPersons with NAFLD had significantly higher levels of the conjugated primary bile acids glycocholic acid (GCA) (POR
conclusionsThe bile acid levels of persons with and without NAFLD differed significantly. Among persons with NAFLD, higher levels of the conjugated forms of CA (i.e. GCA, TCA) and the secondary bile acids that derive from CA (i.e. DCA, TDCA) may indicate there is hepatic overproduction of CA, which may affect the liver via aberrant signalling mediated by the bile acids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.